Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

Table 4 Urinary and plasma L-FABP levels in patients in different stages of DKD

Groups	Urinary L-FABP (μg/ml)	Plasma L-FABP (μg/ml)
Groups	Median (IQR)	Median (IQR)
DM patients with normoalbuminuria (n = 30)	5.9 (5.2, 7.8)	4.4 (2.9,11.3)
DKD patients with microalbuminuria (n = 30)	11.4 (6.7, 13.4)^a	6.7 (3.4,11.4)
DKD patients with macroalbuminuria (n = 30)	18.8 (10.9, 23.4)^a,b	8.6 (2.5,12.4)

^a P < 0.05 compared with the DM patients with normoalbuminuria (Kruskal-Wallis test)
^b P < 0.05 compared with the DKD patients with microalbuminuria (Kruskal-Wallis test)
Abbreviations: IQR interquartile range, serum L-FABP serum liver-type fatty acid binding protein, urinary L-FABP urinary liver-type fatty acid binding protein

ISSN: 2662-7671